The estimated Net Worth of Joseph Frattaroli is at least $363 Thousand dollars as of 19 May 2022. Mr Frattaroli owns over 3,948 units of Inhibikase Therapeutics stock worth over $63,480 and over the last 3 years he sold IKT stock worth over $0. In addition, he makes $300,000 as Chief Financial Officer at Inhibikase Therapeutics.
Mr has made over 1 trades of the Inhibikase Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 3,948 units of IKT stock worth $2,527 on 19 May 2022.
The largest trade he's ever made was buying 3,948 units of Inhibikase Therapeutics stock on 19 May 2022 worth over $2,527. On average, Mr trades about 987 units every 0 days since 2022. As of 19 May 2022 he still owns at least 48,091 units of Inhibikase Therapeutics stock.
You can see the complete history of Mr Frattaroli stock trades at the bottom of the page.
Joseph Frattaroli CPA is the Chief Financial Officer at Inhibikase Therapeutics.
As the Chief Financial Officer of Inhibikase Therapeutics, the total compensation of Mr CPA at Inhibikase Therapeutics is $300,000. There are 1 executives at Inhibikase Therapeutics getting paid more, with Dr. Milton H. Werner having the highest compensation of $307,341.
Mr CPA is 59, he's been the Chief Financial Officer of Inhibikase Therapeutics since . There are no older and 1 younger executives at Inhibikase Therapeutics.
Joseph's mailing address filed with the SEC is 3350 RIVERWOOD PARKWAY SE, SUITE 1900, , ATLANTA, GA, 30339.
Over the last 4 years, insiders at Inhibikase Therapeutics have traded over $0 worth of Inhibikase Therapeutics stock and bought 47,537 units worth $63,897 . The most active insiders traders include Milton H. Werner, Elizabeth G. O'farrell, and Joseph Frattaroli. On average, Inhibikase Therapeutics executives and independent directors trade stock every 57 days with the average trade being worth of $22,267. The most recent stock trade was executed by Milton H. Werner on 16 August 2022, trading 5,000 units of IKT stock currently worth $4,000.
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Inhibikase Therapeutics executives and other stock owners filed with the SEC include: